https://www.selleckchem.com/products/gw5074.html
Non-ESRD IgAN patients did not have an increased overall cancer risk (HR 1.13; 95%CI 0.99-1.3. There was no increased risk of cancer preceding IgAN diagnosis (odds ratio 1.10; 95%CI 0.92-1.32). We found no support for IgAN being a paramalignant condition. There was an increased risk of cancer in IgAN patients, but only for those with ESRD. Our results indicate approximately 6 extra cancer case per 100 IgAN patients with ESRD per 10 years, or 17 extra cases if including NMSC as well. 17 extra cases if including NMSC as well.8-Oxo-7,
Gefällt mir
Kommentar
Teilen
